Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Neoplasms of the CNS

  Free Subscription


Articles published in Neuro Oncol

Retrieve available abstracts of 372 articles:
HTML format
Text format



Single Articles


    June 2017
  1. DIAMOND EL, Prigerson HG, Correa DC, Reiner A, et al
    Prognostic Awareness, Prognostic Communication, and Cognitive Function in Patients with Malignant Glioma.
    Neuro Oncol. 2017 Jun 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. GUTMANN DH
    Caddyshack therapeutics: overcoming glioblastoma adaptation.
    Neuro Oncol. 2017 Jun 16. doi: 10.1093.
    PubMed     Text format    


  3. GALLDIKS N, Albert NL, Sommerauer M, Grosu AL, et al
    PET Imaging in Patients with Meningioma - Report of the RANO/PET Group.
    Neuro Oncol. 2017 Jun 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. WU J, Frady LN, Bash RE, Cohen SM, et al
    MerTK as a therapeutic target in glioblastoma.
    Neuro Oncol. 2017 Jun 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. KIERAN MW, Chisholm J, Casanova M, Brandes AA, et al
    Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.
    Neuro Oncol. 2017 Jun 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. MORROW AM, Morgan RM, Villano JL
    Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials-impact of psychogenic non-epileptic seizures.
    Neuro Oncol. 2017 Jun 6. doi: 10.1093.
    PubMed     Text format    


  7. WANG X, Holgado BL, Ramaswamy V, Mack S, et al
    "miR miR on the wall, who's the most malignant medulloblastoma miR of them all?"
    Neuro Oncol. 2017 Jun 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. ZHOU X, Xie S, Wu S, Qi Y, et al
    Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor.
    Neuro Oncol. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. SEPULVEDA-SANCHEZ JM, Vaz MA, Balana C, Gil-Gil M, et al
    Phase II trial of dacomitinib, a pan-HER (human epidermal growth factor receptor) tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
    Neuro Oncol. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  10. ABUDUMIJITI A, Chan AK, Shi Z, Li Y, et al
    Adult IDH Wild-type Lower-grade Gliomas Should Be Further Stratified.
    Neuro Oncol. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. ZHU C, Kros JM, Cheng C, Mustafa D, et al
    The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.
    Neuro Oncol. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. NABORS LB
    When less is better: care of the elderly with glioblastoma.
    Neuro Oncol. 2017 May 26. doi: 10.1093.
    PubMed     Text format    


  13. GLASS JO, Ogg RJ, Hyun JW, Harreld JH, et al
    Disrupted development and integrity of frontal white matter in patients treated for pediatric medulloblastoma.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. KESARWANI P, Kant S, Prabhu A, Chinnaiyan P, et al
    The interplay between metabolic remodeling and immune regulation in glioblastoma.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. PRABHU A, Kesarwani P, Kant S, Graham SF, et al
    Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. KIERAN MW
    Lessons learned from diffuse intrinsic pontine glioma: how a terrible disease forced us to think better.
    Neuro Oncol. 2017 May 24. doi: 10.1093.
    PubMed     Text format    


  17. JACKSON S, ElAli A, Virgintino D, Gilbert MR, et al
    Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer's disease.
    Neuro Oncol. 2017 May 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. KARIMI S, Vyas MV, Gonen L, Tabasinejad R, et al
    Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. BERGHOFF AS, Kiesel B, Widhalm G, Wilhelm D, et al
    Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. NOWOSIELSKI M, Galldiks N, Iglseder S, Kickingereder P, et al
    Diagnostic Challenges in Meningioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. COLMAN H
    Toward more informative biomarker-based clinical trials in glioblastoma.
    Neuro Oncol. 2017 May 17. doi: 10.1093.
    PubMed     Text format    


  22. GROSSMANN P, Narayan V, Chang K, Rahman R, et al
    Quantitative Imaging Biomarkers for Risk Stratification of Patients with Recurrent Glioblastoma Treated with Bevacizumab.
    Neuro Oncol. 2017 May 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. KILDAY JP, Caldarelli M, Massimi L, Chen RH, et al
    Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN.
    Neuro Oncol. 2017 May 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. SHANKAR GM, Santagata S
    BAP1 mutations in high-grade meningioma: implications for patient care.
    Neuro Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. SCHMIDT C, Schubert NA, Brabetz S, Mack N, et al
    Pre-clinical drug screen reveals topotecan, actinomycin D and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
    Neuro Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. YESILOZ U, Kirches E, Hartmann C, Scholz J, et al
    Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Neuro Oncol. 2017 May 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. SILGINER M, Nagy S, Happold C, Schneider H, et al
    Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma.
    Neuro Oncol. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. NARLOCH JL, Farber SH, Sammons S, McSherry F, et al
    Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.
    Neuro Oncol. 2017 May 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. MASON W
    NANO, a practical scale for neurologic assessments in patients with brain tumors?
    Neuro Oncol. 2017;19:603-604.
    PubMed     Text format    


  30. GITTLEMAN H, Lim D, Kattan MW, Chakravarti A, et al
    An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
    Neuro Oncol. 2017;19:669-677.
    PubMed     Text format     Abstract available


  31. VAN WEST SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, et al
    Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
    Neuro Oncol. 2017;19:719-725.
    PubMed     Text format     Abstract available


  32. TERRIER LM, Bauchet L, Rigau V, Amelot A, et al
    Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database.
    Neuro Oncol. 2017;19:678-688.
    PubMed     Text format     Abstract available


  33. SHAHAR T, Rozovski U, Hess KR, Hossain A, et al
    Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.
    Neuro Oncol. 2017;19:660-668.
    PubMed     Text format     Abstract available


  34. HAN YP, Enomoto A, Shiraki Y, Wang SQ, et al
    Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.
    Neuro Oncol. 2017;19:636-647.
    PubMed     Text format     Abstract available


    April 2017
  35. FIGUEROA JM, Skog J, Akers J, Li H, et al
    Detection of wtEGFR Amplification and EGFRvIII Mutation in CSF-Derived Extracellular Vesicles of Glioblastoma Patients.
    Neuro Oncol. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. WARREN KE, Vezina G, Poussaint TY, Warmuth-Metz M, et al
    Response Assessment in Medulloblastoma and Leptomeningeal Seeding Tumors: Recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee.
    Neuro Oncol. 2017 Apr 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. CAGNEY DN, Martin AM, Catalano PJ, Redig AJ, et al
    Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study.
    Neuro Oncol. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. BROKINKEL B, Hess K, Mawrin C
    Brain invasion in Meningiomas - Clinical considerations and impact of neuropathological evaluation: A systematic Review.
    Neuro Oncol. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. WEIL S, Osswald M, Solecki G, Grosch J, et al
    Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
    Neuro Oncol. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. VITUCCI M, Irvin DM, McNeill RS, Schmid RS, et al
    Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.
    Neuro Oncol. 2017 Apr 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. MITCHELL LA, Lopez Espinoza F, Mendoza D, Kato Y, et al
    Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
    Neuro Oncol. 2017 Apr 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. THOMPSON EM, Keir ST, Venkatraman T, Lascola C, et al
    The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.
    Neuro Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. LIN AL, DeAngelis LM
    Reappraising the 2016 WHO classification for diffuse glioma.
    Neuro Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Text format    


  44. WEN PY, Jiang T, Schiff D
    How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies.
    Neuro Oncol. 2017;19:459-460.
    PubMed     Text format    


  45. GROSSMAN SA, Schreck KC, Ballman K, Alexander B, et al
    Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2017;19:469-474.
    PubMed     Text format    


  46. GROSSHANS DR, Mohan R, Gondi V, Shih HA, et al
    The role of image-guided intensity modulated proton therapy in glioma.
    Neuro Oncol. 2017;19.
    PubMed     Text format     Abstract available


  47. SAHGAL A, Ruschin M, Ma L, Verbakel W, et al
    Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues.
    Neuro Oncol. 2017;19.
    PubMed     Text format     Abstract available


  48. GRANBERG KJ, Annala M, Lehtinen B, Kesseli J, et al
    Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
    Neuro Oncol. 2017 Apr 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  49. AHMED KA, Berglund AE, Welsh EA, Naghavi AO, et al
    The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity.
    Neuro Oncol. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format    


  50. HUANG R
    Response assessment in high-grade glioma: tumor volume as endpoint.
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format    


  51. FOULADI M, Pfister SM
    MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas?
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format    


  52. MCNEILL RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, et al
    Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. COHEN KJ, Jabado N, Grill J
    Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. BLUMENTHAL DT, Gorlia T, Gilbert MR, Kim MM, et al
    Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  55. WU X, Wang Y, Yu T, Nie E, et al
    Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  56. WANG C, Kaprealian TB, Suh JH, Kubicky CD, et al
    Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. HODGES TR, Ott M, Xiu J, Gatalica Z, et al
    Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  58. HOLDHOFF M, Ye X, Supko JG, Nabors LB, et al
    Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
    Neuro Oncol. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. LAWLER SE
    Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment.
    Neuro Oncol. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format    


  60. JEON MS, Dhillon HM, Agar MR
    Sleep disturbance of adults with a brain tumor and their family caregivers: a systematic review.
    Neuro Oncol. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  61. HU X, Martinez-Ledesma E, Zheng S, Kim H, et al
    Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Neuro Oncol. 2017 Mar 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. MEI X, Chen YS, Chen FR, Xi SY, et al
    Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.
    Neuro Oncol. 2017 Mar 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. ALVAREZ-BRECKENRIDGE C, Brastianos PK
    SMO mutant olfactory groove meningiomas-the next in line for targeted therapy.
    Neuro Oncol. 2017;19:305-306.
    PubMed     Text format    


  64. JENKINSON MD, Santarius T, Zadeh G, Aldape KD, et al
    Atypical meningioma-is it time to standardize surgical sampling techniques?
    Neuro Oncol. 2017;19:453-454.
    PubMed     Text format    


    February 2017
  65. ARIF T, Kerlin Y, Nakdimon I, Benharroch D, et al
    VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  66. BANERJEE A, Jakacki RI, Onar-Thomas A, Wu S, et al
    A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  67. COTE DJ, Downer MK, Zoltick ES, Smith TR, et al
    ABO blood group and risk of glioma.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format    


  68. ANDERSON JL, Muraleedharan R, Oatman N, Klotter A, et al
    The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
    Neuro Oncol. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. HUANG YT, Zhang Y, Wu Z, Michaud DS, et al
    Genotype-based gene signature of glioma risk.
    Neuro Oncol. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  70. VAN DEN BENT MJ, Weller M, Wen PY, Kros JM, et al
    A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.
    Neuro Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. TANGUTURI SK, Trippa L, Ramkissoon SH, Pelton K, et al
    Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.
    Neuro Oncol. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  72. FREYSCHLAG CF, Kerschbaumer J, Thome C
    Comment on: Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
    Neuro Oncol. 2017 Feb 18. doi: 10.1093.
    PubMed     Text format    


  73. GAHRMANN R, van den Bent M, van der Holt B, Vernhout RM, et al
    Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  74. HEINZEL A, Muller D, Yekta-Michael SS, Ceccon G, et al
    O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  75. D'ALESSANDRIS QG, Biffoni M, Martini M, Runci D, et al
    The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  76. ABOU-EL-ARDAT K, Seifert M, Becker K, Eisenreich S, et al
    Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  77. MEYRONET D, Esteban-Mader M, Bonnet C, Joly MO, et al
    Characteristics of H3 K27M-mutant gliomas in adults.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  78. TEGLASI V, Reiniger L, Fabian K, Pipek O, et al
    Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed     Text format    


  79. RUDA R, Soffietti R
    Controversies in management of low-grade gliomas in light of new data from clinical trials.
    Neuro Oncol. 2017;19:143-144.
    PubMed     Text format    


  80. RODDY E, Mueller S
    Response to "Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of paediatric brain tumors".
    Neuro Oncol. 2017;19:299-300.
    PubMed     Text format    


  81. PASSOS J, Nzwalo H, Marques J, Azevedo A, et al
    Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of pediatric brain tumors.
    Neuro Oncol. 2017;19:298-299.
    PubMed     Text format    


  82. SOFFIETTI R, Abacioglu U, Baumert B, Combs SE, et al
    Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).
    Neuro Oncol. 2017;19:162-174.
    PubMed     Text format     Abstract available


    January 2017
  83. ZHOU H, Vallieres M, Bai HX, Su C, et al
    MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Neuro Oncol. 2017 Jan 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  84. ANTONIOS JP, Soto H, Everson RG, Moughon D, et al
    Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Neuro Oncol. 2017 Jan 23. pii: now287. doi: 10.1093.
    PubMed     Text format     Abstract available


  85. RAMKISSOON SH, Bandopadhayay P, Hwang J, Ramkissoon LA, et al
    Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.
    Neuro Oncol. 2017 Jan 19. pii: now294. doi: 10.1093.
    PubMed     Text format     Abstract available


  86. COLWELL N, Larion M, Giles AJ, Seldomridge AN, et al
    Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells.
    Neuro Oncol. 2017 Jan 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  87. BERGHOFF AS, Wolpert F, Holland-Letz T, Koller R, et al
    Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.
    Neuro Oncol. 2017 Jan 17. pii: now290. doi: 10.1093.
    PubMed     Text format     Abstract available


  88. BOETTO J, Bielle F, Sanson M, Peyre M, et al
    SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Neuro Oncol. 2017 Jan 12. pii: now276. doi: 10.1093.
    PubMed     Text format     Abstract available


  89. AYUSO JM, Monge R, Martinez-Gonzalez A, Virumbrales-Munoz M, et al
    Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events.
    Neuro Oncol. 2017 Jan 6. pii: now230. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. TENG J, Carla da Hora C, Kantar RS, Nakano I, et al
    Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
    Neuro Oncol. 2017 Jan 6. pii: now253. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. CHAMBERLAIN MC, Baik CS, Gadi VK, Bhatia S, et al
    Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
    Neuro Oncol. 2017;19:i1-i24.
    PubMed     Text format     Abstract available


  92. BOWMAN RL, Wang Q, Carro A, Verhaak RG, et al
    GlioVis data portal for visualization and analysis of brain tumor expression datasets.
    Neuro Oncol. 2017;19:139-141.
    PubMed     Text format    


    December 2016
  93. WIEDMANN MK, Brunborg C, Di Ieva A, Lindemann K, et al
    The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study.
    Neuro Oncol. 2016 Dec 31. pii: now272. doi: 10.1093.
    PubMed     Text format     Abstract available


  94. CICONE F, Galldiks N, Minniti G, Filss CP, et al
    Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury.
    Neuro Oncol. 2016 Dec 31. pii: now283. doi: 10.1093.
    PubMed     Text format    


  95. YOUNG RJ, Yang TJ, Hatzoglou V, Ulaner G, et al
    "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply.
    Neuro Oncol. 2016 Dec 31. pii: now286. doi: 10.1093.
    PubMed     Text format    


  96. MARISETTY AL, Singh SK, Nguyen TN, Coarfa C, et al
    REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.
    Neuro Oncol. 2016 Dec 31. pii: now232. doi: 10.1093.
    PubMed     Text format     Abstract available


  97. ROTH P, Valavanis A, Weller M
    Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
    Neuro Oncol. 2016 Dec 29. pii: now265. doi: 10.1093.
    PubMed     Text format    


  98. KING AA, Seidel K, Di C, Leisenring WM, et al
    Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study.
    Neuro Oncol. 2016 Dec 29. pii: now242. doi: 10.1093.
    PubMed     Text format     Abstract available


  99. REARDON DA, Lassman AB, van den Bent M, Kumthekar P, et al
    Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
    Neuro Oncol. 2016 Dec 29. pii: now257. doi: 10.1093.
    PubMed     Text format     Abstract available


  100. TSCHERPEL C, Dunkl V, Ceccon G, Stoffels G, et al
    The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
    Neuro Oncol. 2016 Dec 29. pii: now243. doi: 10.1093.
    PubMed     Text format     Abstract available


  101. ZHANG AS, Ostrom QT, Kruchko C, Rogers L, et al
    Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010.
    Neuro Oncol. 2016 Dec 29. pii: now252. doi: 10.1093.
    PubMed     Text format     Abstract available


  102. ZAMANIPOOR NAJAFABADI AH, Peeters MC, Dirven L, Lobatto DJ, et al
    Impaired health-related quality of life in meningioma patients-a systematic review.
    Neuro Oncol. 2016 Dec 29. pii: now250. doi: 10.1093.
    PubMed     Text format     Abstract available


  103. TOONEN JA, Ma Y, Gutmann DH
    Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.
    Neuro Oncol. 2016 Dec 29. pii: now267. doi: 10.1093.
    PubMed     Text format     Abstract available


  104. LIU TT, Achrol AS, Mitchell LA, Rodriguez SA, et al
    Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment.
    Neuro Oncol. 2016 Dec 22. pii: now270. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. SHAHAR T, Rozovski U, Hess KR, Hossain A, et al
    Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  106. LEE J, Hoxha E, Song HR
    A novel NFIA-NFkappaB feed-forward loop contributes to glioblastoma cell survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  107. PENG S, Dhurv H, Armstrong B, Salhia B, et al
    Integrated genomic analysis of survival outliers in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  108. HAN YP, Enomoto A, Shiraki Y, Wang SQ, et al
    Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  109. KLEIN M
    Lesion momentum as explanation for preoperative neurocognitive function in patients with malignant glioma.
    Neuro Oncol. 2016;18:1595-1596.
    PubMed     Text format    


  110. SCHIFF D
    Molecular profiling optimizes the treatment of low-grade glioma.
    Neuro Oncol. 2016;18:1593-1594.
    PubMed     Text format    


    November 2016
  111. LASORELLA A, Sanson M, Iavarone A
    FGFR-TACC gene fusions in human glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  112. SHANKAR GM, Abedalthagafi M, Vaubel RA, Merrill PH, et al
    Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
    Neuro Oncol. 2016 Nov 9. doi: 10.1093.
    PubMed     Text format    


  113. ARMSTRONG FD
    Evidence of cerebral microbleeds and neurocognitive impairment following cranial radiation therapy for pediatric brain tumors: a new opportunity for improved care.
    Neuro Oncol. 2016;18:1470-1471.
    PubMed     Text format    


    October 2016
  114. YAGHI NK, Wei J, Hashimoto Y, Kong LY, et al
    Immune modulatory nanoparticle therapeutics for intracerebral glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  115. MENEI P, Clavreul A, Lemee JM
    Response To "Glioma Resection and Tumor Recurrence: Back To Semmelweis".
    Neuro Oncol. 2016.
    PubMed     Text format    


  116. RATEL D, van der Sanden B, Wion D
    Glioma resection and tumor recurrence: back to Semmelweis.
    Neuro Oncol. 2016.
    PubMed     Text format    


    September 2016
  117. PACKER RJ, Pfister S, Bouffet E, Avery R, et al
    Pediatric low-grade gliomas: implications of the biologic era.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  118. VAN WEST SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, et al
    Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  119. AVILA EK, Chamberlain M, Schiff D, Reijneveld JC, et al
    Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  120. WAGNER S, Lanfermann H, Eichner G, Gufler H, et al
    Radiation injury versus malignancy after stereotactic radiosurgery for brain metastases: impact of time-dependent changes in lesion morphology on MRI.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  121. PINHEIRO KV, Alves C, Buendia M, Gil MS, et al
    Targeting tyrosine receptor kinase B in gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


  122. TALASILA KM, Rosland GV, Hagland HR, Eskilsson E, et al
    The angiogenic switch leads to a metabolic shift in human glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  123. GUNDEMIR S, Monteagudo A, Akbar A, Keillor JW, et al
    The complex role of transglutaminase 2 in glioblastoma proliferation.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  124. KEBIR S, Rauschenbach L, Galldiks N, Schlaak M, et al
    Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.
    Neuro Oncol. 2016.
    PubMed     Text format    


  125. GUNDEMIR S, Monteagudo A, Akbar A, Keillor JW, et al
    The complex role of transglutaminase 2 in glioblastoma proliferation.
    Neuro Oncol. 2016 Sep 2. doi: 10.1093.
    PubMed     Text format    


  126. BERENDSEN S, Snijders TJ, Robe PA
    Response to: "Prognostic relevance of epilepsy at presentation in lower-grade gliomas".
    Neuro Oncol. 2016;18:1327-8.
    PubMed     Text format    


  127. WATTS C, Langen KJ
    PET imaging in glioma: is it time for mainstream practice?
    Neuro Oncol. 2016;18:1193-4.
    PubMed     Text format    


    August 2016
  128. ELLINGSON BM, Harris RJ, Woodworth DC, Leu K, et al
    Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single- and multicenter trials.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  129. TERRIER LM, Bauchet L, Rigau V, Amelot A, et al
    Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  130. NELSON SJ, Kadambi AK, Park I, Li Y, et al
    Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  131. GOMEZ-ROMAN N, Stevenson K, Gilmour L, Hamilton G, et al
    A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  132. WEFEL JS, Noll KR, Rao G, Cahill DP, et al
    Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  133. ROSENBERG S, Verreault M, Schmitt C, Guegan J, et al
    Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  134. KIM EH, Lee JH, Oh Y, Koh I, et al
    Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  135. WAHL M, Phillips JJ, Molinaro AM, Lin Y, et al
    Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  136. YANG R, Sarkar S, Korchinski DJ, Wu Y, et al
    MRI monitoring of monocytes to detect immune stimulating treatment response in brain tumor.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  137. MCTYRE ER, Johnson AG, Ruiz J, Isom S, et al
    Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  138. NGUYEN HN, Lie A, Li T, Chowdhury R, et al
    Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  139. RIGGS L, Piscione J, Laughlin S, Cunningham T, et al
    Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  140. RODDY E, Sear K, Felton E, Tamrazi B, et al
    Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  141. KANN BH, Lester-Coll NH, Park HS, Yeboa DN, et al
    Adjuvant chemotherapy and overall survival in adult medulloblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  142. BERGHOFF AS, Preusser M
    In search of a target: PD-1 and PD-L1 profiling across glioma types.
    Neuro Oncol. 2016.
    PubMed     Text format    


  143. VERMEULEN JF, van Hecke W, Jansen MK, Spliet WG, et al
    No evidence for human cytomegalovirus infection in pediatric medulloblastomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


  144. WICK W, Chinot OL, Bendszus M, Mason W, et al
    Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  145. HU LS, Ning S, Eschbacher JM, Baxter LC, et al
    Radiogenomics to characterize regional genetic heterogeneity in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  146. PATEL P, Baradaran H, Delgado D, Askin G, et al
    MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  147. ARVOLD ND, Lee EQ, Mehta MP, Margolin K, et al
    Updates in the management of brain metastases.
    Neuro Oncol. 2016;18:1043-65.
    PubMed     Text format     Abstract available


    July 2016
  148. LI S, Zeng A, Hu Q, Yan W, et al
    miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  149. CECCON G, Lohmann P, Stoffels G, Judov N, et al
    Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  150. ZIEGLER J, Pody R, Coutinho de Souza P, Evans B, et al
    ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  151. LEHMAN NL, Hattab EM, Mobley BC, Usubalieva A, et al
    Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  152. JAFARI-KHOUZANI K, Loebel F, Bogner W, Rapalino O, et al
    Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  153. DUNET V, Prior JO
    Response to: Performance of 18F-FET-PET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: inherent bias in meta-analysis not revealed by quality metrics.
    Neuro Oncol. 2016;18:1029-30.
    PubMed     Text format    


  154. HUANG X, Bai H, Zhou H, Tang H, et al
    Performance of 18F-FET-PET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: inherent bias in meta-analysis not revealed by quality metrics.
    Neuro Oncol. 2016;18:1028.
    PubMed     Text format    


  155. LASSALETTA A, Ramaswamy V
    Medulloblastoma in adults: they're not just big kids.
    Neuro Oncol. 2016;18:895-7.
    PubMed     Text format    


  156. BARONE TA, Burkhart CA, Safina A, Haderski G, et al
    Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  157. GOFFART N, Lombard A, Lallemand F, Kroonen J, et al
    CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  158. HASHIZUME R, Zhang A, Mueller S, Prados MD, et al
    Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  159. WICK W, Roth P, Hartmann C, Hau P, et al
    Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  160. ZHOU H, Huang X, Bai HX, Tan X, et al
    Prognostic relevance of epilepsy at presentation in lower-grade gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


    June 2016
  161. LIN H, Patel S, Affleck VS, Wilson I, et al
    Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  162. ZHANG B, Chang K, Ramkissoon S, Tanguturi S, et al
    Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  163. BURTH S, Kickingereder P, Eidel O, Tichy D, et al
    Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  164. OKOLIE O, Bago JR, Schmid RS, Irvin DM, et al
    Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  165. VANNINI E, Olimpico F, Middei S, Ammassari-Teule M, et al
    Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron structure and function.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  166. ARMSTRONG TS, Shade MY, Breton G, Gilbert MR, et al
    Sleep-wake disturbance in patients with brain tumors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  167. MANGANI D, Weller M, Seyed Sadr E, Willscher E, et al
    Limited role for transforming growth factor-beta pathway activation-mediated escape from VEGF inhibition in murine glioma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  168. ESKILSSON E, Rosland GV, Talasila KM, Knappskog S, et al
    EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  169. JONES C, Karajannis MA, Jones DT, Kieran MW, et al
    Pediatric high-grade glioma: biologically and clinically in need of new thinking.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  170. SCHIFF D
    PCV in low-grade gliomas: benefit from old drugs in an evolving disease entity.
    Neuro Oncol. 2016;18:755-6.
    PubMed     Text format    


    May 2016
  171. ESKILSSON E, Verhaak RG
    Longitudinal genomic characterization of brain tumors for identification of therapeutic vulnerabilities.
    Neuro Oncol. 2016.
    PubMed     Text format    


  172. FOUNTAIN DM, Allen D, Joannides AJ, Nandi D, et al
    Reporting of patient-reported health-related quality of life in adults with diffuse low-grade glioma: a systematic review.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  173. GUHASARKAR D, Su Q, Gao G, Sena-Esteves M, et al
    Systemic AAV9-IFNbeta gene delivery treats highly invasive glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  174. LEBLANC AK, Mazcko C, Brown DE, Koehler JW, et al
    Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  175. BERNARD-ARNOUX F, Lamure M, Ducray F, Aulagner G, et al
    The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  176. YAGIZ K, Huang TT, Lopez Espinoza F, Mendoza D, et al
    Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  177. NAGASHIMA H, Tanaka K, Sasayama T, Irino Y, et al
    Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  178. CHANG K, Zhang B, Guo X, Zong M, et al
    Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  179. DE FEYTER HM, Behar KL, Rao JU, Madden-Hennessey K, et al
    A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  180. ZADEH G, Karimi S, Aldape KD
    PIK3CA mutations in meningioma.
    Neuro Oncol. 2016;18:603-4.
    PubMed     Text format    


    April 2016
  181. LAKS DR, Crisman TJ, Shih MY, Mottahedeh J, et al
    Large-scale assessment of the gliomasphere model system.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  182. ZHANG X, Rao A, Sette P, Deibert C, et al
    IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  183. LEDUR PF, Liu C, He H, Harris AR, et al
    Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  184. ZHAO F, Ohgaki H, Xu L, Giangaspero F, et al
    Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  185. MCDONALD CR, Delfanti RL, Krishnan AP, Leyden KM, et al
    Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  186. ALBERT NL, Weller M, Suchorska B, Galldiks N, et al
    Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  187. SEYSTAHL K, Stoecklein V, Schuller U, Rushing E, et al
    Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  188. CORREA DD, Satagopan J, Cheung K, Arora AK, et al
    COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  189. GRANT R, Brown PD
    Fatigue randomized controlled trials-how tired is "too tired" in patients undergoing glioma treatment?
    Neuro Oncol. 2016.
    PubMed     Text format    


  190. PATIL SS, Gokulnath P, Bashir M, Shwetha SD, et al
    Insulin-like growth factor binding protein-2 regulates beta-catenin signaling pathway in glioma cells and together contributes to poor patient prognosis.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  191. LEE HJ, Hanibuchi M, Kim SJ, Yu H, et al
    Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.
    Neuro Oncol. 2016;18:486-96.
    PubMed     Text format     Abstract available


  192. OSSWALD M, Solecki G, Wick W, Winkler F, et al
    A malignant cellular network in gliomas: potential clinical implications.
    Neuro Oncol. 2016;18:479-85.
    PubMed     Text format     Abstract available


    March 2016
  193. COOK PJ, Thomas R, Kingsley PJ, Shimizu F, et al
    Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  194. LULLA RR, Goldman S, Yamada T, Beattie CW, et al
    Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  195. SZABO E, Schneider H, Seystahl K, Rushing EJ, et al
    Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  196. CHINOT OL, Nishikawa R, Mason W, Henriksson R, et al
    Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  197. YUE X, Cao D, Lan F, Pan Q, et al
    MiR-301a is activated by the Wnt/beta-catenin pathway and promotes glioma cell invasion by suppressing SEPT7.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  198. JAKACKI RI, Cohen KJ, Buxton A, Krailo MD, et al
    Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  199. GIELEN PR, Schulte BM, Kers-Rebel ED, Verrijp K, et al
    Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  200. CORDOVA JS, Shu HG, Liang Z, Gurbani SS, et al
    Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  201. POLLACK IF, Jakacki RI, Butterfield LH, Hamilton RL, et al
    Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomasdagger.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  202. PIAO Y, Park SY, Henry V, Smith BD, et al
    Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  203. PISKLAKOVA A, McKenzie B, Zemp F, Lun X, et al
    M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  204. YANG P, Cai J, Yan W, Zhang W, et al
    Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  205. XIPELL E, Aragon T, Martinez-Velez N, Vera B, et al
    Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  206. OSTERBERG N, Ferrara N, Vacher J, Gaedicke S, et al
    Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  207. NIGIM F, Esaki SI, Hood M, Lelic N, et al
    A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  208. BRANDES AA, Finocchiaro G, Zagonel V, Reni M, et al
    AVAREG: a phase 2, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  209. PUROW B
    For glioma, a sweet side to diabetes.
    Neuro Oncol. 2016;18:306-7.
    PubMed     Text format    


  210. HELFER JL, Wen PY, Blakeley J, Gilbert MR, et al
    Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
    Neuro Oncol. 2016;18 Suppl 2:ii26-ii36.
    PubMed     Text format     Abstract available


  211. BLAKELEY JO, Coons SJ, Corboy JR, Leidy NK, et al
    Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.
    Neuro Oncol. 2016;18 Suppl 2:ii13-ii20.
    PubMed     Text format     Abstract available


  212. ARMSTRONG TS, Bishof AM, Brown PD, Klein M, et al
    Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.
    Neuro Oncol. 2016;18 Suppl 2:ii1-ii12.
    PubMed     Text format     Abstract available


  213. BALLESTER LY, Olar A, Roy-Chowdhuri S
    Next-generation sequencing of central nervous systems tumors: the future of personalized patient management.
    Neuro Oncol. 2016;18:308-10.
    PubMed     Text format    


    February 2016
  214. KATHAGEN-BUHMANN A, Schulte A, Weller J, Holz M, et al
    Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  215. SHOJI T, Saito R, Chonan M, Shibahara I, et al
    Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  216. JALBERT LE, Neill E, Phillips JJ, Lupo JM, et al
    Magnetic resonance analysis of malignant transformation in recurrent glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  217. STELLA GM, Senetta R, Inghilleri S, Verdun di Cantogno L, et al
    MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer.
    Neuro Oncol. 2016.
    PubMed     Text format    


  218. BRANDES AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, et al
    A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  219. LEE EQ, Muzikansky A, Drappatz J, Kesari S, et al
    A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  220. KLINE CN, Joseph NM, Grenert JP, van Ziffle J, et al
    Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas.
    Neuro Oncol. 2016.
    PubMed     Text format    


  221. VOGELBAUM MA
    The benefit of surgical resection in recurrent glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format    


  222. SOMMERAUER M, Burkhardt JK, Frontzek K, Rushing E, et al
    68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  223. WHEELER LA, Manzanera AG, Bell SD, Cavaliere R, et al
    Phase 2 multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  224. FRANCESCHI S, Lessi F, Aretini P, Mazzanti CM, et al
    Molecular portrait of a rare case of metastatic glioblastoma: somatic and germline mutations using whole-exome sequencing.
    Neuro Oncol. 2016;18:298-300.
    PubMed     Text format    


  225. KESSLER T
    Predicting glioblastoma response to bevacizumab through marker profiling?
    Neuro Oncol. 2016;18:149-50.
    PubMed     Text format    


  226. ALEXANDER BM
    Radiation de-intensification for patients with glioblastoma and poor prognostic features-how much do we really know?
    Neuro Oncol. 2016;18:147-8.
    PubMed     Text format    


  227. BAUMGARTEN P, Blank AE, Franz K, Hattingen E, et al
    Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Neuro Oncol. 2016;18:173-83.
    PubMed     Text format     Abstract available


  228. RUDA R, Bosa C, Magistrello M, Franchino F, et al
    Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
    Neuro Oncol. 2016;18:261-8.
    PubMed     Text format     Abstract available


    January 2016
  229. KERBEL RS
    Exploiting drug repositioning and the brain microenvironment to treat brain metastases.
    Neuro Oncol. 2016.
    PubMed     Text format    


  230. SCHMID RS, Simon JM, Vitucci M, McNeill RS, et al
    Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  231. ABEDALTHAGAFI M, Bi WL, Aizer AA, Merrill PH, et al
    Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  232. SUCHORSKA B, Weller M, Tabatabai G, Senft C, et al
    Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  233. ALKINS R, Burgess A, Kerbel R, Wels WS, et al
    Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  234. SARAN F, Chinot OL, Henriksson R, Mason W, et al
    Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  235. KIM MM, Parmar H, Cao Y, Knox SJ, et al
    Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.
    Neuro Oncol. 2016.
    PubMed     Text format    


  236. THORNE AH, Zanca C, Furnari F
    Epidermal growth factor receptor targeting and challenges in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  237. SANCHEZ-OSUNA M, Martinez-Escardo L, Granados-Colomina C, Martinez-Soler F, et al
    An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells.
    Neuro Oncol. 2016.
    PubMed     Text format     Abstract available


  238. SOFFIETTI R, Ruda R, Trakul N, Chang EL, et al
    Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis?
    Neuro Oncol. 2016;18:12-5.
    PubMed     Text format    


  239. OSTROM QT, Gittleman H, de Blank PM, Finlay JL, et al
    American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.
    Neuro Oncol. 2016;18 Suppl 1:i1-i50.
    PubMed     Text format    


  240. SCHIFF D
    Quantifying the burden of primary central nervous system malignancy.
    Neuro Oncol. 2016;18:5-6.
    PubMed     Text format    


  241. ROUSE C, Gittleman H, Ostrom QT, Kruchko C, et al
    Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010.
    Neuro Oncol. 2016;18:70-7.
    PubMed     Text format     Abstract available


  242. LEE JK, Chang N, Yoon Y, Yang H, et al
    USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance.
    Neuro Oncol. 2016;18:37-47.
    PubMed     Text format     Abstract available


    December 2015
  243. DE LA FUENTE MI, Young RJ, Rubel J, Rosenblum M, et al
    Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  244. HATZOGLOU V, Yang TJ, Omuro A, Gavrilovic I, et al
    A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  245. EATON BR, Esiashvili N, Kim S, Patterson B, et al
    Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  246. WIRSCHING HG, Morel C, Gmur C, Neidert MC, et al
    Predicting outcome of epilepsy after meningioma resection.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  247. HOVER LD, Owens P, Munden AL, Wang J, et al
    Bone morphogenetic protein signaling promotes tumorigenesis in a murine model of high-grade glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  248. XU Z, Zeng X, Xu J, Xu D, et al
    Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  249. DI K, Lloyd GK, Abraham V, MacLaren A, et al
    Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  250. WEI J, Nduom EK, Kong LY, Hashimoto Y, et al
    MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  251. MOLINARO AM, Wrensch MR, Jenkins RB, Eckel-Passow JE, et al
    Statistical considerations on prognostic models for glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  252. HWANG WL, Marciscano AE, Niemierko A, Kim DW, et al
    Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  253. XUAN F, Huang M, Liu W, Ding H, et al
    Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  254. DUBINSKI D, Wolfer J, Hasselblatt M, Schneider-Hohendorf T, et al
    CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  255. ROELCKE U, Wyss MT, Nowosielski M, Ruda R, et al
    Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  256. STAFFORD JH, Hirai T, Deng L, Chernikova SB, et al
    Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  257. ZHANG M, Gulotta B, Thomas A, Kaley T, et al
    Large-volume low lesion predicts poor survival in bevacizumab-treated glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  258. CAHILL KE, Morshed RA, Yamini B
    Nuclear factor-kappaB in glioblastoma: insights into regulators and targeted therapy.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  259. ARMSTRONG TS, Grant R, Gilbert MR, Lee JW, et al
    Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available



  260. A new clinical guideline from the Royal College of Paediatrics and Child Health with a national awareness campaign accelerates brain tumor diagnosis in UK children-"HeadSmart: Be Brain Tumour Aware".
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  261. NDUOM EK, Weller M, Heimberger AB
    Immunosuppressive mechanisms in glioblastoma.
    Neuro Oncol. 2015;17 Suppl 7:vii9-vii14.
    PubMed     Text format     Abstract available


    October 2015
  262. LIU X, Madhankumar AB, Miller PA, Duck KA, et al
    MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  263. TAKANO K, Kinoshita M, Takagaki M, Sakai M, et al
    Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  264. ROGERS CL, Perry A, Pugh S, Vogelbaum MA, et al
    Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  265. POUSSAINT TY, Vajapeyam S, Ricci KI, Panigrahy A, et al
    Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  266. JASSAM SA, Maherally Z, Smith JR, Ashkan K, et al
    TNF-alpha enhancement of CD62E mediates adhesion of non-small cell lung cancer cells to brain endothelium via CD15 in lung-brain metastasis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  267. WICK W, Platten M, Wick A, Hertenstein A, et al
    Current status and future directions of anti-angiogenic therapy for gliomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  268. VELDHUIJZEN VAN ZANTEN SE, van Meerwijk CL, Jansen MH, Twisk JW, et al
    Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  269. BUTOWSKI N, Colman H, De Groot JF, Omuro AM, et al
    Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  270. VAN DER VOS KE, Abels ER, Zhang X, Lai C, et al
    Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  271. NOLL KR, Wefel JS
    Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function".
    Neuro Oncol. 2015;17:1421-2.
    PubMed     Text format    


  272. KANE JR
    From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function.
    Neuro Oncol. 2015;17:1420-1.
    PubMed     Text format    


  273. MANSOURI S, Zadeh G
    Neddylation in glioblastomas.
    Neuro Oncol. 2015;17:1305-6.
    PubMed     Text format    


    September 2015
  274. WALBERT T, Pace A
    End-of-life care in patients with primary malignant brain tumors: early is better.
    Neuro Oncol. 2015.
    PubMed     Text format    


  275. JONES KA, Gilder AS, Lam MS, Du N, et al
    Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  276. BERENDSEN S, Varkila M, Kroonen J, Seute T, et al
    Prognostic relevance of epilepsy at presentation in glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  277. HOU L, Jiang J, Liu B, Han W, et al
    Smoking and adult glioma: a population-based case-control study in China.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  278. COCKLE JV, Rajani K, Zaidi S, Kottke T, et al
    Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  279. WANG K, Wang Y, Fan X, Wang J, et al
    Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  280. MORANA G, Piccardo A, Puntoni M, Nozza P, et al
    Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  281. HABETS EJ, Dirven L, Wiggenraad RG, Verbeek-de Kanter A, et al
    Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  282. HELLWINKEL JE, Redzic JS, Harland TA, Gunaydin D, et al
    Glioma-derived extracellular vesicles selectively suppress immune responses.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  283. HEGI ME, Stupp R
    Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma?
    Neuro Oncol. 2015.
    PubMed     Text format    


  284. ALVARADO AG, Turaga SM, Sathyan P, Mulkearns-Hubert EE, et al
    Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  285. SHIROISHI MS, Boxerman JL, Pope WB
    Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  286. FILBIN MG, Segal RA
    How neuronal activity regulates glioma cell proliferation.
    Neuro Oncol. 2015.
    PubMed     Text format    


  287. OBEROI RK, Parrish KE, Sio TT, Mittapalli RK, et al
    Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  288. KOCAKAYA S, Beier CP, Beier D
    Chemotherapy increases long-term survival in patients with adult medulloblastoma-a literature-based meta-analysis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  289. FURTNER J, Schopf V, Seystahl K, Le Rhun E, et al
    Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  290. DUBBINK HJ, Atmodimedjo PN, Kros JM, French PJ, et al
    Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  291. BERTOLINI F, Pecchi A, Stefani A, Fontana A, et al
    Everolimus effectively blocks pulmonary metastases from meningioma.
    Neuro Oncol. 2015;17:1301-2.
    PubMed     Text format    


  292. SUL J, Krainak DM
    Brain tumor clinical trials imaging: a (well-standardized) picture is worth a thousand words.
    Neuro Oncol. 2015;17:1179-80.
    PubMed     Text format    


  293. EVERSON RG, Antonios JP, Lisiero DN, Soto H, et al
    Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  294. NDUOM EK, Wei J, Yaghi NK, Huang N, et al
    PD-L1 expression and prognostic impact in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  295. AIZER AA, Abedalthagafi M, Linda Bi W, Horvath MC, et al
    A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  296. XIA S, Lal B, Tung B, Wang S, et al
    Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  297. ARMSTRONG TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, et al
    The symptom burden of primary brain tumors: evidence for a core set of tumor and treatment-related symptoms.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available



  298. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
    Neuro Oncol. 2015.
    PubMed     Text format    


  299. DIAMOND EL, Russell D, Kryza-Lacombe M, Bowles KH, et al
    Rates and risks for late referral to hospice in patients with primary malignant brain tumors.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  300. ZHU Y, Zhao K, Prinz A, Keyvani K, et al
    Loss of endothelial programmed cell death 10 activates glioblastoma cells and promotes tumor growth.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  301. BLUML S, Margol AS, Sposto R, Kennedy RJ, et al
    Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  302. ELLINGSON BM, Bendszus M, Boxerman J, Barboriak D, et al
    Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  303. DAVIS B, Shen Y, Poon CC, Luchman HA, et al
    Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  304. TOGAO O, Hiwatashi A, Yamashita K, Kikuchi K, et al
    Differentiation of high-grade and low-grade diffuse gliomas by intravoxel incoherent motion MR imaging.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  305. DUNET V, Pomoni A, Hottinger A, Nicod-Lalonde M, et al
    Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  306. RINGEL F, Pape H, Sabel M, Krex D, et al
    Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  307. TABOURET E, Boudouresque F, Farina P, Barrie M, et al
    MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.
    Neuro Oncol. 2015;17:1174-6.
    PubMed     Text format    


  308. NOWAK J, Seidel C, Pietsch T, Alkonyi B, et al
    Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified.
    Neuro Oncol. 2015;17:1157-65.
    PubMed     Text format     Abstract available


  309. POPE WB
    Predictive imaging marker of bevacizumab efficacy: perfusion MRI.
    Neuro Oncol. 2015;17:1046-7.
    PubMed     Text format    


    July 2015
  310. LUPO JM, Molinaro AM, Essock-Burns E, Butowski N, et al
    The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with gliomadagger.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  311. WALKER PR, Migliorini D
    The CD40/CD40L axis in glioma progression and therapy.
    Neuro Oncol. 2015.
    PubMed     Text format    


  312. LEMEE JM, Clavreul A, Menei P
    Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  313. WANGARYATTAWANICH P, Hatami M, Wang J, Thomas G, et al
    Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  314. PALLUD J, Audureau E, Noel G, Corns R, et al
    Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  315. FRIEDMAN GK, Moore BP, Nan L, Kelly VM, et al
    Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  316. MACYSZYN L, Akbari H, Pisapia JM, Da X, et al
    Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  317. WAITKUS MS, Diplas BH, Yan H
    Isocitrate dehydrogenase mutations in gliomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  318. HARSHYNE LA, Nasca BJ, Kenyon LC, Andrews DW, et al
    Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  319. OUYANG Q, Chen G, Zhou J, Li L, et al
    Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  320. AGNIHOTRI S, Zadeh G
    Metabolic reprogramming in glioblastoma: The influence of cancer metabolism on epigenetics and unanswered questions.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  321. BADVE C, Sloan AE
    Modeling the growth dynamics of glioblastoma using magnetic resonance imaging.
    Neuro Oncol. 2015.
    PubMed     Text format    


  322. COBBS C
    Reply to: Towards an unbiased, collaborative effort to reach evidence about the presence of human cytomegalovirus in glioblastoma (and other tumors).
    Neuro Oncol. 2015;17:1040.
    PubMed     Text format    


  323. MICHAELIS M, Mittelbronn M, Cinatl J Jr
    Towards an unbiased, collaborative effort to reach evidence about the presence of human cytomegalovirus in glioblastoma (and other tumors).
    Neuro Oncol. 2015;17:1039.
    PubMed     Text format    


  324. MEHTA MP
    The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients.
    Neuro Oncol. 2015;17:919-23.
    PubMed     Text format    


  325. SAHGAL A
    Point/Counterpoint: Stereotactic radiosurgery without whole-brain radiation for patients with a limited number of brain metastases: the current standard of care?
    Neuro Oncol. 2015;17:916-8.
    PubMed     Text format    


  326. WEN PY
    Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases.
    Neuro Oncol. 2015;17:915.
    PubMed     Text format    


  327. GUNN ME, Malila N, Lahdesmaki T, Arola M, et al
    Late new morbidity in survivors of adolescent and young-adulthood brain tumors in Finland: a registry-based study.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  328. GONG Y, Ma Y, Sinyuk M, Loganathan S, et al
    Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  329. MASON WP
    Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  330. KREHER S, Johrens K, Strehlow F, Martus P, et al
    Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
    Neuro Oncol. 2015;17:1016-21.
    PubMed     Text format     Abstract available


    June 2015
  331. FIELD KM, Simes J, Nowak AK, Cher L, et al
    Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  332. GALLDIKS N, Langen KJ, Pope WB
    From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  333. ABHINAV K, Yeh FC, Mansouri A, Zadeh G, et al
    High-definition fiber tractography for the evaluation of perilesional white matter tracts in high-grade glioma surgery.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  334. HARRIS RJ, Cloughesy TF, Liau LM, Prins RM, et al
    pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  335. ACQUAYE AA, Lin L, Vera-Bolanos E, Gilbert MR, et al
    Hope and mood changes throughout the primary brain tumor illness trajectory.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  336. FEICHTINGER RG, Weis S, Mayr JA, Zimmermann FA, et al
    Alterations of oxidative phosphorylation in meningiomas and peripheral nerve sheath tumors.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  337. SELIGER C, Ricci C, Meier CR, Bodmer M, et al
    Diabetes, use of antidiabetic drugs, and the risk of glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  338. BOSNYAK E, Kamson DO, Guastella AR, Varadarajan K, et al
    Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  339. BADHIWALA JH, Almenawer SA
    Extent of surgical resection of high-grade glioma among the elderly.
    Neuro Oncol. 2015;17:903-4.
    PubMed     Text format    


    May 2015
  340. WEN PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, et al
    Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  341. WALSH KM, Wiencke JK, Lachance DH, Wiemels JL, et al
    Telomere maintenance and the etiology of adult glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  342. PATEL KR, Lawson DH, Kudchadkar RR, Carthon BC, et al
    Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  343. ZHOU Y, Wu S, Liang C, Lin Y, et al
    Transcriptional upregulation of microtubule-associated protein 2 is involved in the protein kinase A-induced decrease in the invasiveness of glioma cells.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  344. GALLDIKS N, Stoffels G, Filss C, Rapp M, et al
    The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  345. CHONAN M, Saito R, Shoji T, Shibahara I, et al
    CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  346. GERSTNER ER, Ye X, Duda DG, Levine MA, et al
    A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  347. KSHETTRY VR, Ostrom QT, Kruchko C, Al-Mefty O, et al
    Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  348. NICLOU SP
    Gauging heterogeneity in primary versus recurrent glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  349. BECKER CM, Oberoi RK, McFarren SJ, Muldoon DM, et al
    Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format     Abstract available


  350. LIM M
    Immunotherapy for glioblastoma: are we finally getting closer?
    Neuro Oncol. 2015.
    PubMed     Text format    


  351. SCHIFF D, Sarkaria J
    Dasatinib in recurrent glioblastoma: failure as a teacher.
    Neuro Oncol. 2015.
    PubMed     Text format    


  352. VLAHOVIC G, Fecci PE, Reardon D, Sampson JH, et al
    Programmed death-ligand 1(PD-L1) as an immunotherapy target in patients with glioblastoma.
    Neuro Oncol. 2015.
    PubMed     Text format    


  353. ACHARYA S, DeWees T, Shinohara ET, Perkins SM, et al
    Long-term outcomes and late effects for childhood and young adulthood intracranial germinomas.
    Neuro Oncol. 2015;17:741-6.
    PubMed     Text format     Abstract available


  354. MUNCH TN, Gortz S, Wohlfahrt J, Melbye M, et al
    The long-term risk of malignant astrocytic tumors after structural brain injury--a nationwide cohort study.
    Neuro Oncol. 2015;17:718-24.
    PubMed     Text format     Abstract available


  355. LEE J, Dang X, Borboa A, Coimbra R, et al
    Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation.
    Neuro Oncol. 2015;17:685-96.
    PubMed     Text format     Abstract available


  356. HORNQUIST L, Rickardsson J, Lannering B, Gustafsson G, et al
    Altered self-perception in adult survivors treated for a CNS tumor in childhood or adolescence: population-based outcomes compared with the general population.
    Neuro Oncol. 2015;17:733-40.
    PubMed     Text format     Abstract available


    April 2015
  357. AVULA S, Kumar R, Pizer B, Pettorini B, et al
    Diffusion abnormalities on intraoperative magnetic resonance imaging as an early predictor for the risk of posterior fossa syndrome.
    Neuro Oncol. 2015;17:614-22.
    PubMed     Text format     Abstract available


  358. CHAKRAVADHANULA M, Hampton CN, Chodavadia P, Ozols V, et al
    Wnt pathway in atypical teratoid rhabdoid tumors.
    Neuro Oncol. 2015;17:526-35.
    PubMed     Text format     Abstract available


  359. GAO Y, Whitaker-Dowling P, Barmada MA, Basse PH, et al
    Viral infection of implanted meningeal tumors induces antitumor memory T-cells to travel to the brain and eliminate established tumors.
    Neuro Oncol. 2015;17:536-44.
    PubMed     Text format     Abstract available


    March 2015
  360. ZADEH G, Khan OH, Vogelbaum M, Schiff D, et al
    Much debated controversies of diffuse low-grade gliomas.
    Neuro Oncol. 2015;17:323-6.
    PubMed     Text format    


  361. ZACH L, Guez D, Last D, Daniels D, et al
    Delayed contrast extravasation MRI: a new paradigm in neuro-oncology.
    Neuro Oncol. 2015;17:457-65.
    PubMed     Text format     Abstract available


  362. TSUI K, Gajjar A, Li C, Srivastava D, et al
    Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy.
    Neuro Oncol. 2015;17:448-56.
    PubMed     Text format     Abstract available


  363. ZHI F, Shao N, Wang R, Deng D, et al
    Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma.
    Neuro Oncol. 2015;17:383-91.
    PubMed     Text format     Abstract available


  364. VERA-BOLANOS E, Aldape K, Yuan Y, Wu J, et al
    Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.
    Neuro Oncol. 2015;17:440-7.
    PubMed     Text format     Abstract available


    February 2015
  365. IWAMOTO FM, Lassman AB
    Factorial clinical trials: a new approach to phase II neuro-oncology studies.
    Neuro Oncol. 2015;17:174-6.
    PubMed     Text format    


  366. ALEXANDER BM, Galanis E, Yung WK, Ballman KV, et al
    Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.
    Neuro Oncol. 2015;17:180-8.
    PubMed     Text format     Abstract available


  367. PACHOW D, Wick W, Gutmann DH, Mawrin C, et al
    The mTOR signaling pathway as a treatment target for intracranial neoplasms.
    Neuro Oncol. 2015;17:189-99.
    PubMed     Text format     Abstract available


    January 2015
  368. OSTROM QT, de Blank PM, Kruchko C, Petersen CM, et al
    Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.
    Neuro Oncol. 2015;16 Suppl 10:x1-x36.
    PubMed     Text format     Abstract available


  369. MCNEILL RS, Vitucci M, Wu J, Miller CR, et al
    Contemporary murine models in preclinical astrocytoma drug development.
    Neuro Oncol. 2015;17:12-28.
    PubMed     Text format     Abstract available


  370. LEE JS, Park JR, Kwon OS, Lee TH, et al
    SIRT1 is required for oncogenic transformation of neural stem cells and for the survival of "cancer cells with neural stemness" in a p53-dependent manner.
    Neuro Oncol. 2015;17:95-106.
    PubMed     Text format     Abstract available


  371. WANG J, Pulido JS, O'Neill BP, Johnston PB, et al
    Second malignancies in patients with primary central nervous system lymphoma.
    Neuro Oncol. 2015;17:129-35.
    PubMed     Text format     Abstract available


    September 2014
  372. PALLUD J, Duffau H
    Is a prospective trial necessary to suggest a clinical relevance?
    Neuro Oncol. 2014;16:1295-6.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: